ASX announcement here.
Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the Company. In the interim, operational matters would be managed by the chairman, Mr. Tony Ho and the CFO Mr. Jarrod White.
Dr. Comans is an associate of Mariposa Health Limited.
The directors of BXN wish to thank Dr. Comans for his contributions and look forward to continue working with MHL to successfully commercialise the HI-164OV.
For more information contact:Tony Ho +61 417 345 839 Non-executive chairman